Kostandinos Sideras, M.D., Ph.D.

Publicaciones

  1. van Es N, Ventresca M, Di Nisio M, Zhou Q, Noble S, Crowther M, Briel M, Garcia D, Lyman GH, Macbeth F, Griffiths G, Iorio A, Mbuagbaw L, Lawrence M, Neumann I, Brozek J, Guyatt G, Streiff MB, Baldeh T, Florez ID, Gurunlu Alma O, Agnelli G, Ageno W, Marcucci M, Bozas G, Zulian G, Maraveyas A, Lebeau B, Lecumberri R, Sideras K, Loprinzi C, McBane R, Pelzer U, Riess H, Solh Z, Perry J, Kahale LA, Bossuyt PM, Klerk C, Buller HR, Akl EA, Schunemann HJ, IPDMA Heparin Use in Cancer Patients Research Group. The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. J Thromb Haemost. 2020 Aug; 18 (8):1940-1951 Epub 2020 July 08
    View PubMed
  2. Boor PPC, Sideras K, Biermann K, Hosein Aziz M, Levink IJM, Mancham S, Erler NS, Tang X, van Eijck CH, Bruno MJ, Sprengers D, Zang X, Kwekkeboom J. HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis. Br J Cancer. 2020 Apr; 122 (8):1211-1218 Epub 2020 Feb 19
    View PubMed
  3. Sideras K, de Man RA, Harrington SM, Polak WG, Zhou G, Schutz HM, Pedroza-Gonzalez A, Biermann K, Mancham S, Hansen BE, Bart Takkenberg R, van Vuuren AJ, Pan Q, Ijzermans JNM, Sleijfer S, Sprengers D, Dong H, Kwekkeboom J, Bruno MJ. Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels. Sci Rep. 2019 Jul 23; 9 (1):10677 Epub 2019 July 23
    View PubMed
  4. Aziz MH, Sideras K, Aziz NA, Mauff K, Haen R, Roos D, Saida L, Suker M, van der Harst E, Mieog JS, Bonsing BA, Klaver Y, Koerkamp BG, van Eijck CH. The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study. Ann Surg. 2019 Jul; 270 (1):139-146
    View PubMed
  5. Liu P, Cao W, Ma B, Li M, Chen K, Sideras K, Duitman JW, Sprengers D, Khe Tran TC, Ijzermans JNM, Biermann K, Verheij J, Spek CA, Kwekkeboom J, Pan Q, Peppelenbosch MP. Action and clinical significance of CCAAT/enhancer-binding protein delta in hepatocellular carcinoma. Carcinogenesis. 2019 Mar 12; 40 (1):155-163
    View PubMed
  6. Wang W, Li S, Liu P, Sideras K, van de Werken HJG, van der Heide M, Cao W, Lavrijsen M, Peppelenbosch MP, Bruno M, Pan Q, Smits R. Oncogenic STRAP Supports Hepatocellular Carcinoma Growth by Enhancing Wnt/beta-Catenin Signaling. Mol Cancer Res. 2019 Feb; 17 (2):521-531 Epub 2018 Sept 26
    View PubMed
  7. Ma B, Chen K, Liu P, Li M, Liu J, Sideras K, Sprengers D, Biermann K, Wang W, IJzermans JNM, Cao W, Kwekkeboom J, Peppelenbosch MP, Pan Q. Dichotomal functions of phosphorylated and unphosphorylated STAT1 in hepatocellular carcinoma. J Mol Med (Berl). 2019 Jan; 97 (1):77-88 Epub 2018 Nov 19
    View PubMed
  8. Sideras K, Galjart B, Vasaturo A, Pedroza-Gonzalez A, Biermann K, Mancham S, Nigg AL, Hansen BE, Stoop HA, Zhou G, Verhoef C, Sleijfer S, Sprengers D, Kwekkeboom J, Bruno MJ. Prognostic value of intra-tumoral CD8(+) /FoxP3(+) lymphocyte ratio in patients with resected colorectal cancer liver metastasis. J Surg Oncol. 2018 Jul; 118 (1):68-76 Epub 2018 June 07
    View PubMed
  9. Jasim S, Suman VJ, Jimenez C, Harris P, Sideras K, Burton JK, Worden FP, Auchus RJ, Bible KC. Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma. Endocrine. 2017 Aug; 57 (2):220-225 Epub 2017 July 06
    View PubMed
  10. Sideras K, Biermann K, Yap K, Mancham S, Boor PPC, Hansen BE, Stoop HJA, Peppelenbosch MP, van Eijck CH, Sleijfer S, Kwekkeboom J, Bruno MJ. Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer. Int J Cancer. 2017 Aug 1; 141 (3):572-582 Epub 2017 May 19
    View PubMed
  11. Sideras K, Biermann K, Verheij J, Takkenberg BR, Mancham S, Hansen BE, Schutz HM, de Man RA, Sprengers D, Buschow SI, Verseput MC, Boor PP, Pan Q, van Gulik TM, Terkivatan T, Ijzermans JN, Beuers UH, Sleijfer S, Bruno MJ, Kwekkeboom J. PD-L1, Galectin-9 and CD8(+) tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. Oncoimmunology. 2017; 6 (2):e1273309 Epub 2017 Jan 03
    View PubMed
  12. Moroso V, van Cranenbroek B, Mancham S, Sideras K, Boor PP, Biermann K, de Vogel L, de Knegt RJ, van der Eijk A, van der Laan LJ, de Jonge J, Metselaar HJ, Joosten I, Kwekkeboom J. Prominent HLA-G Expression in Liver Disease But Not After Liver Transplantation. Transplantation. 2015 Dec; 99 (12):2514-22
    View PubMed
  13. Hernanda PY, Chen K, Das AM, Sideras K, Wang W, Li J, Cao W, Bots SJ, Kodach LL, de Man RA, Ijzermans JN, Janssen HL, Stubbs AP, Sprengers D, Bruno MJ, Metselaar HJ, ten Hagen TL, Kwekkeboom J, Peppelenbosch MP, Pan Q. SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma. Oncogene. 2015 Sep 24; 34 (39):5055-68 Epub 2014 Dec 22
    View PubMed
  14. Sideras K, Bots SJ, Biermann K, Sprengers D, Polak WG, IJzermans JN, de Man RA, Pan Q, Sleijfer S, Bruno MJ, Kwekkeboom J. Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area. Br J Cancer. 2015 Jun 9; 112 (12):1911-20
    View PubMed
  15. Connolly RM, Leal JP, Goetz MP, Zhang Z, Zhou XC, Jacobs LK, Mhlanga J, O JH, Carpenter J, Storniolo AM, Watkins S, Fetting JH, Miller RS, Sideras K, Jeter SC, Walsh B, Powers P, Zorzi J, Boughey JC, Davidson NE, Carey LA, Wolff AC, Khouri N, Gabrielson E, Wahl RL, Stearns V. TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer. J Nucl Med. 2015 Jan; 56 (1):31-7 Epub 2014 Dec 04
    View PubMed
  16. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Karlin N, Sideras K, Morris JC 3rd, McIver B, Hay I, Fatourechi V, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Cher Goh B, Isham CR, Harris P, Erlichman C, Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer Center, and the Mayo Phase 2 Consortium. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab. 2014 May; 99 (5):1687-93 Epub 2014 Feb 25
    View PubMed
  17. Sideras K, Braat H, Kwekkeboom J, van Eijck CH, Peppelenbosch MP, Sleijfer S, Bruno M. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat Rev. 2014 May; 40 (4):513-22 Epub 2013 Nov 23
    View PubMed
  18. Sideras K, Kwekkeboom J. Cancer inflammation and inflammatory biomarkers: can neutrophil, lymphocyte, and platelet counts represent the complexity of the immune system? Transpl Int. 2014 Jan; 27 (1):28-31
    View PubMed
  19. Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young DE, Zhao C, Chia YL, Hoch U, Hannah AL, Perez EA, NKTR-102 Study Group. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncol. 2013 Nov; 14 (12):1216-25 Epub 2013 Oct 04
    View PubMed
  20. Sideras K, Dueck AC, Hobday TJ, Rowland KM Jr, Allred JB, Northfelt DW, Lingle WL, Behrens RJ, Fitch TR, Nikcevich DA, Perez EA. North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane. Clin Breast Cancer. 2012 Dec; 12 (6):387-91 Epub 2012 Oct 17
    View PubMed
  21. Bible KC, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Lloyd R, Eberhardt NL, Reddi HV, Casler JD, Karlin NJ, Westphal SA, Richardson RL, Buckner JC, Erlichman C. Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers. Am J Manag Care. 2012 May 1; 18 (5):e162-7 Epub 2012 May 01
    View PubMed
  22. Bible KC, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Eberhardt NL, Reddi HV, Casler JD, Karlin NJ, Westphal SA, Richardson RL, Buckner JC, Erlichman C. Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers. J Oncol Pract. 2012 May; 8 (3 Suppl):e1s-5s
    View PubMed
  23. Moraska AR, Moraska JM, Sideras K, Loprinzi CL. Management of hot flashes in breast cancer patients. European J Clin Med Oncol. 2012; 4(1):1-9.
  24. Sideras K, Loprinzi CL. Nonhormonal management of hot flashes for women on risk reduction therapy. J Natl Compr Canc Netw. 2010 Oct; 8 (10):1171-9
    View PubMed
  25. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C, Endocrine Malignancies Disease Oriented Group//Mayo Clinic Cancer Center//Mayo Phase 2 Consortium. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010 Oct; 11 (10):962-72 Epub 2010 Sept 17
    View PubMed
  26. Sideras K, Menefee ME, Burton JK, Erlichman C, Bible KC, Ivy SP. Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib. J Clin Oncol. 2010 Jul 1; 28 (19):e312-3 Epub 2010 June 01
    View PubMed
  27. Sideras K, Ingle JN, Ames MM, Loprinzi CL, Mrazek DP, Black JL, Weinshilboum RM, Hawse JR, Spelsberg TC, Goetz MP. Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol. 2010 Jun 1; 28 (16):2768-76 Epub 2010 May 03
    View PubMed
  28. Sideras K, Gertz MA. Amyloidosis. Adv Clin Chem. 2009; 47:1-44
    View PubMed
  29. Sideras K, Zahasky KM, Kaur JS. Response of cutaneous metastases from breast cancer to capecitabine. Clin Med Oncol. 2008; 2:415-8 Epub 2008 Apr 18
    View PubMed
  30. Bolona ER, Uraga MV, Haddad RM, Tracz MJ, Sideras K, Kennedy CC, Caples SM, Erwin PJ, Montori VM. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007 Jan; 82 (1):20-8
    View PubMed
  31. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Bolona ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007 Jan; 82 (1):29-39
    View PubMed
  32. Tracz MJ, Sideras K, Bolona ER, Haddad RM, Kennedy CC, Uraga MV, Caples SM, Erwin PJ, Montori VM. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab. 2006 Jun; 91 (6):2011-6 Epub 2006 May 23
    View PubMed
  33. Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, Dakhil SR, Levitt R, Alberts SR, Morton RF, Rowland KM, Novotny PJ, Loprinzi CL. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc. 2006 Jun; 81 (6):758-67
    View PubMed
  34. Jatoi A, Sideras K, Nguyen PL. Tumor Necrosis Factor-alpha as a Treatment Target for the Cancer Anorexia/Weight Loss Syndrome. Support Cancer Ther. 2004 Jul 1; 1 (4):237-42
    View PubMed
  35. Luisi DL, Kuhlman B, Sideras K, Evans PA, Raleigh DP. Effects of varying the local propensity to form secondary structure on the stability and folding kinetics of a rapid folding mixed alpha/beta protein: characterization of a truncation mutant of the N-terminal domain of the ribosomal protein L9. J Mol Biol. 1999 May 28; 289 (1):167-74
    View PubMed
PST-20469876